118 related articles for article (PubMed ID: 36829269)
1. Development of HPLC-MS/MS assay for quantitation of ensartinib in human plasma and its application to a pharmacokinetics study in Chinese patients.
Li H; Wang Y; Chen X; Chen C; Cui J; Han Y; Ding L
Biomed Chromatogr; 2023 May; 37(5):e5610. PubMed ID: 36829269
[TBL] [Abstract][Full Text] [Related]
2. An UPLC-MS/MS method to determine CT-707 and its two metabolites in plasma of ALK-positive advanced non-small cell lung cancer patients.
Cui C; Hu P; Jiang J; Kong F; Luo H; Zhao Q
J Pharm Biomed Anal; 2018 May; 153():1-8. PubMed ID: 29455091
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous determination of dacomitinib and its major metabolite, O-desmethyl dacomitinib in human plasma by LC-MS/MS and its application to clinical testing in patients with non-small cell lung cancer.
Feng X; Ding Y; Zhang P; Fu Q; Zhang L; Zheng H
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Oct; 1182():122940. PubMed ID: 34564058
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous and rapid determination of 12 tyrosine kinase inhibitors by LC-MS/MS in human plasma: Application to therapeutic drug monitoring in patients with non-small cell lung cancer.
Zhou L; Wang S; Chen M; Huang S; Zhang M; Bao W; Bao A; Zhang P; Guo H; Liu Z; Xie G; Gao J; Wu Z; Lou Y; Fan G
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Jun; 1175():122752. PubMed ID: 33991955
[TBL] [Abstract][Full Text] [Related]
5. Mass balance, metabolic disposition, and pharmacokinetics of [
Zhou S; Liu W; Zhou C; Zhang L; Xie L; Xu Z; Wang L; Zhao Y; Guo L; Chen J; Ding L; Mao L; Tao Y; Zhang C; Ding S; Shao F
Cancer Chemother Pharmacol; 2020 Dec; 86(6):719-730. PubMed ID: 33044566
[TBL] [Abstract][Full Text] [Related]
6. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients.
Reis R; Labat L; Allard M; Boudou-Rouquette P; Chapron J; Bellesoeur A; Thomas-Schoemann A; Arrondeau J; Giraud F; Alexandre J; Vidal M; Goldwasser F; Blanchet B
J Pharm Biomed Anal; 2018 Sep; 158():174-183. PubMed ID: 29883880
[TBL] [Abstract][Full Text] [Related]
7. A high-performance liquid chromatography-tandem mass spectrometry method for the determination of lifrafenib, a novel RAF kinase and EGFR inhibitor, in human plasma and urine and its application in clinical pharmacokinetic study.
Yao X; Song L; Liu Y; Wang H; Liu J; Jiang J; Liu D; Hu P
J Pharm Biomed Anal; 2019 Mar; 166():20-29. PubMed ID: 30599278
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous determination of alflutinib and its active metabolite in human plasma using liquid chromatography-tandem mass spectrometry.
Liu X; Li W; Zhang Y; Jiang Y; Zhao Q; Zhong D
J Pharm Biomed Anal; 2019 Nov; 176():112735. PubMed ID: 31394305
[TBL] [Abstract][Full Text] [Related]
9. Development of an LC-MS/MS method for quantifying ASK120067, a novel mutant-selective inhibitor of the epidermal growth factor receptor (EGFR) as well as its main metabolite in human plasma and its application in a pharmacokinetic study.
Cui X; Wang S; Gao H; Li B; Shi Y; Guo H; Song T; Zheng X
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Jan; 1162():122488. PubMed ID: 33360679
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial.
Yang Y; Zhou J; Zhou J; Feng J; Zhuang W; Chen J; Zhao J; Zhong W; Zhao Y; Zhang Y; Song Y; Hu Y; Yu Z; Gong Y; Chen Y; Ye F; Zhang S; Cao L; Fan Y; Wu G; Guo Y; Zhou C; Ma K; Fang J; Feng W; Liu Y; Zheng Z; Li G; Wu N; Song W; Liu X; Zhao S; Ding L; Mao L; Selvaggi G; Yuan X; Fu Y; Wang T; Xiao S; Zhang L
Lancet Respir Med; 2020 Jan; 8(1):45-53. PubMed ID: 31628085
[TBL] [Abstract][Full Text] [Related]
11. Quantification and pharmacokinetics of crizotinib in rats by liquid chromatography-tandem mass spectrometry.
Qiu F; Gu Y; Wang T; Gao Y; Li X; Gao X; Cheng S
Biomed Chromatogr; 2016 Jun; 30(6):962-8. PubMed ID: 26467669
[TBL] [Abstract][Full Text] [Related]
12. Determination of Puquitinib in Human Plasma by HPLC-ESI MS/MS: Application to Pharmacokinetic Study.
Zhan J; Ding Y; Zou B; Liao H; Jiang W; Li S
Eur J Drug Metab Pharmacokinet; 2018 Oct; 43(5):555-564. PubMed ID: 29520719
[TBL] [Abstract][Full Text] [Related]
13. Development of an UPLC-MS/MS method for quantification of Avitinib (AC0010) and its five metabolites in human cerebrospinal fluid: Application to a study of the blood-brain barrier penetration rate of non-small cell lung cancer patients.
Wang W; Zheng X; Wang H; Wang L; Jiang J; Hu P
J Pharm Biomed Anal; 2017 May; 139():205-214. PubMed ID: 28285073
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China.
Luo X; Zhou Z; Zeng X; Peng L; Liu Q
Front Public Health; 2022; 10():985834. PubMed ID: 36211665
[TBL] [Abstract][Full Text] [Related]
15. A highly sensitive and selective method for the determination of leukotriene B4 (LTB4) in ex vivo stimulated human plasma by ultra fast liquid chromatography-tandem mass spectrometry.
Lin W; Huang MQ; Xue X; Bertelsen K; Chen G; Zhao H; Lin ZJ; Fourie A; de Jong J; Weng N
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Apr; 925():54-62. PubMed ID: 23523878
[TBL] [Abstract][Full Text] [Related]
16. An LC-MS/MS method for quantification of AC0010, a novel mutant-selective epidermal growth factor receptor (EGFR) inhibitor, and its metabolites in human plasma and the application to a pharmacokinetic study.
Wang L; Zheng X; Wang W; Hu P; Jiang J
J Pharm Biomed Anal; 2017 Jul; 141():9-18. PubMed ID: 28414972
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of a novel LC-MS/MS method for simultaneous quantitative determination of tyrosine kinase inhibitors in human plasma.
Lou Y; Qin H; Hu Q; Chai Y; Zhou H; Chen M; Wang Q; Huang P; Gu J; Zhang Y
J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Oct; 1208():123394. PubMed ID: 35932695
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous determination of calycosin-7-O-β-D-glucoside, cinnamic acid, paeoniflorin and albiflorin in rat plasma by UHPLC-MS/MS and its application to a pharmacokinetic study of Huangqi Guizhi Wuwu Decoction.
Guan J; Wang L; Jin J; Chang S; Xiao X; Feng B; Zhu H
J Pharm Biomed Anal; 2019 Jun; 170():1-7. PubMed ID: 30897430
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous determination of 11 alkaloids in rat plasma by LC-ESI-MS/MS and a pharmacokinetic study after oral administration of total alkaloids extracted from Naucleaofficinalis.
Wang G; Wang H; Lin Z; Hou L; Wang JY; Sun L
J Ethnopharmacol; 2022 Jan; 282():114560. PubMed ID: 34454053
[TBL] [Abstract][Full Text] [Related]
20. A New Validated HPLC-MS/MS Method for Quantification and Pharmacokinetic Evaluation of Dovitinib, a Multi-Kinase Inhibitor, in Mouse Plasma.
AlRabiah H; Kadi AA; Aljohar HI; Attwa MW; Al-Shakliah NS; Attia SM; Mostafa GA
Drug Des Devel Ther; 2020; 14():407-415. PubMed ID: 32095071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
